Eleni Efstathiou

Career Trajectory

Research Cluster Map

Direct collaborators. Node size = influence, colour = community, dashed = past collaboration.

• Physician perspectives on the implementability of a cardiovascular risk score for prostate cancer: A PRISM-guided evaluation.

  Journal of Clinical Oncology · 2026-03-01

• Niraparib and abiraterone acetate plus prednisone for HRR-deficient metastatic castration-sensitive prostate cancer: a randomized phase 3 trial

  Nature Medicine · 2025-10-07 · 42 citations

• Disease Detection Rate of Combination Ga-68 PSMA-PET/CT and Whole-Body MRI in Biochemical Recurrence After Prostatectomy

  Proceedings on CD-ROM - International Society for Magnetic Resonance in Medicine. Scientific Meeting and Exhibition/Proceedings of the International Society for Magnetic Resonance in Medicine, Scientific Meeting and Exhibition · 2025-09-16

• Barriers and solutions for healthcare professionals to involve patients as partners in oncology research: Project RISE

  Future Oncology · 2025-06-11 · 2 citations

• Phase 3 AMPLITUDE trial: Niraparib (NIRA) and abiraterone acetate plus prednisone (AAP) for metastatic castration-sensitive prostate cancer (mCSPC) patients (pts) with alterations in homologous recombination repair (HRR) genes.

  Journal of Clinical Oncology · 2025-06-04 · 17 citations

• Niraparib and Abiraterone Acetate plus Prednisone in Metastatic Castration-resistant Prostate Cancer: Final Overall Survival Analysis for the Phase 3 MAGNITUDE Trial

  European Urology Oncology · 2025-05-05 · 22 citations

• IP26-28 COMPARISON OF CARDIOVASCULAR EVENTS IN PATIENTS WITH ADVANCED PROSTATE CANCER TREATED WITH LUTEINIZING HORMONE RELEASING HORMONE AGONISTS VERSUS ANTAGONISTS IN THE US: AN ANALYSIS OF THE TRINETX DATABASE

  The Journal of Urology · 2025-04-08

• A plain language summary of the results from the MAGNITUDE study assessing how effective and how safe niraparib and abiraterone acetate with prednisone is in patients with metastatic castration-resistant prostate cancer

  Future Oncology · 2025-03-30 · 1 citations

• The Role of Dynamic Contrast Enhanced Magnetic Resonance Imaging in Evaluating Prostate Adenocarcinoma: A Partially‐Blinded Retrospective Study of a Prostatectomy Patient Cohort With Whole Gland Histopathology Correlation and Application of PI‐RADS or TNM Staging

  The Prostate · 2024-12-19 · 4 citations

• The role of Cabazitaxel in Patients With Castration-Resistant and Osseous Metastases Prostate Cancer. A Hellenic Cooperative Oncology Group Phase II Study

  Clinical Genitourinary Cancer · 2024-10-28 · 1 citations

• Management of Patients with Advanced Prostate Cancer. Report from the 2024 Advanced Prostate Cancer Consensus Conference (APCCC)

  European Urology · 2024-10-11 · 115 citations

• Patient-reported Outcomes for Patients with Metastatic Castration-resistant Prostate Cancer and BRCA1/2 Gene Alterations: Final Analysis from the Randomized Phase 3 MAGNITUDE Trial

  European Urology · 2024-09-23 · 13 citations